Pre-clinical study.
Agree it is undervalued, however AGN is several years ahead on the clinical timeline - having completed a phase 1 and started dosing in a placebo-controlled double-blind phase 2. Plus ODD designation for HIE. I'd argue that AGN is also undervalued.
Ann: Nyrada Commences Walter Reed Traumatic Brain Injury Study, page-3
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $10.22M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 5.8¢ | 5.6¢ | $14.12K | 245.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 79794 | 5.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.3¢ | 127843 | 1 |
View Market Depth
| Last trade - 15.50pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
5.7¢ |
Change
-0.001 ( 1.72 %) |
||||
| Open | High | Low | Volume | ||
| 5.9¢ | 5.9¢ | 5.6¢ | 90169 | ||
| Last updated 15.50pm 31/05/2024 ? | |||||
| NYR (ASX) Chart |